Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) Levels and Its Association with Renal Allograft Rejection
Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) Levels and Its Association with Renal Allograft Rejection
复制标题
DOI：
10.1080/08820139.2016.1248559
复制
发表时间：
2017-04-01
影响因子：
2.8
通讯作者：
Abid, Aiysha
中科院分区：
文献类型：
--
作者：
Raza, Ali;Firasat, Sadaf;Abid, Aiysha
背景：CCL 2是单核细胞/巨噬细胞、T细胞和自然杀伤细胞的化学引诱物。它参与了移植肾的免疫反应。本研究旨在探讨尿CCL 2表达对肾移植患者排斥反应发生的预测作用。样本包括（a）活检证实的移植物排斥（n = 165）;（B）非排斥（n = 93）;（c）非活检稳定移植物（n = 42）和（d）健康肾供体（n = 109）。使用MCP-1/CCL 2 ELISA试剂盒定量样品的CCL 2。结果：与非排斥组、稳定移植组和对照组相比，排斥组CCL 2水平明显升高，差异有统计学意义（P < 0.05）。受试者工作曲线的特点表明，尿CCL 2水平是一个很好的预测移植物排斥反应，与曲线下面积为0.81 - 0.03，最佳灵敏度和特异性分别为87%和62%，在截止值为198 pg/mL。Kaplan-Meier曲线还显示，与CCL 2表达水平大于198 pg/mL的组相比，CCL 2表达水平小于198 pg/mL的组的累积无排斥移植物存活时间更好（30周vs.3周;对数秩检验，P < 0.001）。这表明，CCL 2，与其他标志物，可能有助于早期检测和监测移植排斥反应的发生。
Background: CCL2 is a chemoattractant for monocytes/macrophages, T cells, and natural killer cells. It is shown to be involved in the immunological responses against renal allograft. This study was conducted to access the role of urinary CCL2 expression in predicting the rejection episodes in renal transplant patients.Method: A total of 409 urine samples included in this study. The samples were consisted of (a) biopsy-proven graft rejection (n = 165); (b) non-rejection (n = 93); (c) non-biopsy stable-graft (n = 42), and (d) healthy renal donors (n = 109). The samples were quantified for the CCL2 using the MCP-1/CCL2 ELISA kit. The data were analyzed using the Statistical Package for Social Sciences (SPSS (R)) and MedCalc((R)) statistical software.Results: Results showed that the CCL2 levels were significantly increased in rejection group when compared with the non-rejection, stable-graft, and control, P < 0.05. The receiver operating curve's characteristics illustrated that the urinary CCL2 level is a good predictor for graft rejection, with an area under the curve of 0.81 0.03 with optimum sensitivity and specificity of 87% and 62%, respectively, at a cut-off value of 198 pg/mL. Kaplan-Meier curve also showed better cumulative rejection-free graft survival time in group with less than 198 pg/mL of CCL2 as compared to those with expression levels of more than 198 pg/mL (30 weeks vs. 3 weeks; log-rank test, P < 0.001).Conclusion: In our study, noninvasive investigation of CCL2 levels in urine has showed potential to predict rejection episodes. It is suggested that the CCL2, with others markers, may help in early detection and monitoring of graft rejection episodes.